Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + cetuximab + radiotherapy feasibility study in cisplatin-unfit locally advanced head and neck squamous cell carcinoma
NL-OMON46250Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of avelumab and cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Primary endpoint: toxicity. Started Feb 2017; status: active, not recruiting.
02
Drugs
avelumabcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON46250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46250.